This site is intended for Healthcare Professionals outside the US

Recommended dosing in PV1

JAKAVI is to be given orally twice a day (BID)1

Recommended dose

  • Starting dose for most patients: 10 mg BID1
  • Maximum dose: 25 mg BID1

Available strengths of tablets1

JAKAVI dosing for Polycythemia Vera patients

Tablets shown are not actual size.

Important considerations for starting therapy with JAKAVI1

  • A complete blood cell count must be performed before initiating therapy with JAKAVI
  • There is limited information to recommend a starting dose for patients with platelet counts between 50,000/mm3 and 100,000/mm3
  • The starting dose should not be increased during the first 4 weeks of treatment

Dose modifications

  • Doses may be titrated based on safety and efficacy1

Dose adjustments during treatment by blood count1

JAKAVI dose adjustments for Polycythemia Vera treatment by blood count

Dose adjustments based on response to treatment1

JAKAVI dose adjustments for Polycythemia Vera treatment

The starting dose should not be increased during the first 4 weeks of treatment, and thereafter no more frequently than at 2-week intervals. Maximum dose is 25 mg BID.

Treatment duration

  • Treatment may be continued as long as the benefit/risk ratio remains positive1

Download the JAKAVI for PV dosing guide

Next: RESPONSE study design

Reference:

  1. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; April 2015.